Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria
John M. Kane, Eran Harary, Roy Eshet, Orna Tohami, Mark Weiser, Stefan Leucht, Avia Merenlender‐Wagner, Nir Sharon, Glen L Davis, Mark Suett, Kelli R. Franzenburg, Christoph U. Correll
Topics & Concepts
RisperidoneDiscontinuationMedicinePlaceboPopulationClinical endpointRandomized controlled trialInternal medicinePediatricsSchizophrenia (object-oriented programming)Clinical trialPsychiatryAlternative medicineEnvironmental healthPathologySchizophrenia research and treatmentHealthcare Decision-Making and RestraintsPharmaceutical studies and practices